John Norwood, MD
Internal Medicine · Jonesboro, ARNPI 1114984069
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Merck at 59.5% of the total. Reporting peaked in 2023 at $7,420 and has fallen 91.8% since, to $609 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $131.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$12K
- Viiv Healthcare Company$6K
- AbbVie$818
- La Jolla Pharmaceutical Company$668
- Gilead$416
- Insmed, Inc.$330
- plus $261 from 7 others
Across 2 payments — averaging $800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Veru Inc.$2K
What the payments were for
- Consulting fees$12,28859%
- Travel & lodging$4,45421%
- Food & beverage$3,93119%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 34 | $12,335 |
| Viiv Healthcare Company | 15 | $5,893 |
| AbbVie(2 entities) | 42 | $818 |
| La Jolla Pharmaceutical Company | 29 | $668 |
| Gilead | 10 | $416 |
| Insmed, Inc. | 17 | $330 |
| Janssen Products, LP | 1 | $94 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $63 |
| Abiomed | 1 | $35 |
| AstraZeneca(2 entities) | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,721 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 39 | $130,934 |
| Daptomycin | 53 | $118,117 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $54,105 |
| IsentressRaltegravir Potassium | 19 | $41,791 |
| Vancomycin Hcl | 53 | $11,029 |
| Darunavir | 12 | $9,558 |
| CeftriaxoneCeftriaxone Sodium | 48 | $8,075 |
| Meropenem | 40 | $7,371 |
| Itraconazole | 12 | $6,386 |
| Rifabutin | 13 | $5,836 |
| Cefepime Hcl | 15 | $4,022 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 12 | $1,899 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 27 | $1,048 |
| Levothyroxine Sodium | 14 | $1,016 |
| Doxycycline Hyclate | 45 | $832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato | $5,893 | $130,93439 claims |
| GileadBiktarvy | $416 | $54,10512 claims |
| MerckIsentress | $12,335 | $41,79119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Jonesboro
- David PyleJonesboro$93K
- Revel PorterJonesboro$12K
- Ricky TateJonesboro$11K
- Brannon TreeceJonesboro$9K
- Veryl HodgesJonesboro$8K
- Corey DiamondJonesboro$8K
- Veronica EastonJonesboro$5K
- Ben OwensJonesboro$5K
- Stephen PaceJonesboro$5K
- Aaron StrobelLittle Rock$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.